secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protalix BioTherapeutics, Inc. (PLX)
CIK:        0001006281
Form:       8-K
Filed at:   2025-04-23T23:59:59+00:00
Accession:  0001558370-25-005275
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protalix CFO Eyal Rubin resigns; to serve six-month transition through Oct 2025
-------------------------------------------------------------------------------

- Eyal Rubin, Sr. VP & CFO, provided six months' notice on April 21, 2025 to pursue other opportunities.
- He will continue in his role for the six-month period and assist with transition.
- Compensation Committee agreed to full salary, benefits, and equity incentives during the period.
- Upon termination, he will receive two months' salary severance and full accelerated vesting of unvested equity.
- No successor has been appointed; earlier termination possible with mutual agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1006281/000155837025005275/0001558370-25-005275-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1006281/000155837025005275/plx-20250421x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-005275

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer